CJC-1295 (no DAC)
★ 90Modified GRF 1-29
GHRH analog — amplifies the natural GH pulse
Muscle GrowthAbout
A synthetic GHRH (Growth Hormone Releasing Hormone) analog that activates pituitary GHRH receptors. Without DAC, the short half-life preserves natural pulsatility.
Mechanism
Binds GHRH receptors in pituitary somatotrophs, stimulating GH production and release.
Dosage
beginner
- Amount
- 100 mcg
- Frequency
- 1x per day before sleep
- Route
- SubQ
- Duration
- 8-12 weeks
standard
- Amount
- 100-200 mcg
- Frequency
- 1-2x per day
- Route
- SubQ
- Duration
- 12-16 weeks
advanced
- Amount
- 200-300 mcg
- Frequency
- 2-3x per day (synced with meals)
- Route
- SubQ
- Duration
- 16 weeks with a 4-week break
Best on an empty stomach, 30-60 min before food or sleep. Almost always paired with Ipamorelin.
12-16 weeks on, 4 weeks off
Reconstitution & Storage
Can be combined with Ipamorelin in the same syringe (same concentration).
Dosing reference — units to draw
Concentration = peptide mass ÷ bacteriostatic water; units to draw = dose volume (mL) × 100 on a U-100 insulin syringe. Each vial size below is shown at 2 mL, with the units to draw for a typical 200–1000 mcg dose.
| Vial | BAC water | Concentration | Units to draw |
|---|---|---|---|
| 5 mg | 2 mL | 2500 mcg/mL | 8–40 units |
| 10 mg | 2 mL | 5000 mcg/mL | 4–20 units |
Lyophilized: freezer. Reconstituted: 2-8°C, 28 days.
Benefits
- • Raises GH and IGF-1
- • Muscle building
- • Fat loss (especially visceral)
- • Improved sleep
- • Slower aging
- • Improved energy and recovery
Side effects
- • Facial flushing — transient
- • Tingling
- • Headache
- • Fluid retention (rare)
Contraindications
- • Active cancer
- • Pregnancy
- • Pituitary disease
- • Insulin resistance (caution)
Gender notes
Men
Common stack: 200 mcg + 200 mcg Ipamorelin nightly.
Women
Start at 100 mcg + 100 mcg Ipamorelin. Sensitivity is higher.
Research
- Teichman SL et al: CJC-1295 sustained GH release ↗
Trial of CJC-1295 with and without DAC, showing sustained GH and IGF-1 elevation.
Journal of Clinical Endocrinology & Metabolism · 2006
- Ionescu M, Frohman LA: CJC-1295 in healthy adults ↗
Clinical trial of CJC-1295 in healthy adults.
Journal of Clinical Endocrinology & Metabolism · 2006
Stacks well with
CJC-1295 (no DAC) FAQ
How do you reconstitute CJC-1295 (no DAC)?
Add 2 mL of bacteriostatic water to a 5 mg vial of CJC-1295 (no DAC), which gives a concentration of 2500 mcg/mL. Inject the water slowly down the vial wall and swirl gently — never shake.
What is a typical CJC-1295 (no DAC) dose?
A typical research dose of CJC-1295 (no DAC) is 200–1000 mcg, 1-2x per day. This is educational information, not medical advice.
How many units of CJC-1295 (no DAC) do I draw?
From a 5 mg vial reconstituted with 2 mL of bacteriostatic water, draw 8–40 units on a U-100 insulin syringe for a 200–1000 mcg dose.
Track CJC-1295 (no DAC) doses in the app
Built-in reconstitution calculator, dose log, and reminders. Free on Android.
Get on Google PlayEducational use only. Not medical advice. Many peptides shown are not FDA-approved and remain research compounds. Always consult a qualified healthcare provider.